摘要
目的 建立抗血管紧张素Ⅱ 1型受体 (AT1 受体 )自身抗体和抗α1 肾上腺素能受体 (α1 受体 )自身抗体的间接酶联免疫吸附法 (ELISA) ,并探讨这两种抗体与高血压的关系。方法 以合成的AT1 受体和α1 受体细胞外第二环功能表位肽段 (AT1 16 5~ 191和α1 192~ 2 18位氨基酸序列 )作抗原 ,建立ELISA方法 ,检测 98例降压未达标组、96例降压达标组患者和 4 0名正常人血清中抗AT1 受体和α1 受体自身抗体。结果 阳性参考血清批内和批间变异系数分别为 0 0 6 6、0 0 72和 0 0 97、0 10 1,用抗原吸收后 ,吸光度 (A)值分别降低 2 5倍和 2 3倍 ,98例降压未达标高血压患者中抗AT1 受体自身抗体和抗α1 受体自身抗体阳性率分别为 4 1 8% ,36 7% ,明显高于降压达标组患者(10 4 2 %、13 5 4 % )和正常血压组 (7 5 %、5 % ) ,均P <0 0 1。结论 抗AT1 受体自身抗体和抗α1 受体自身抗体检测法的特异性和敏感性高、操作简便 。
Objective To establish the method of screening the autoantibodies against the angiotensin Ⅱ type 1 receptor(AT1 receptor) and the α1 adrenergic receptor by enzyme linked immunosorbent assay (ELISA)and to evaluate the relationship between the autoantibodies and hypertension Methods The epitope of the extracellular loops (amino acid sequence from 165 to 191) of AT1 receptor and (amino acid sequence from 192 to 218) of α1 adrenergic receptor were synthesized and used as antigens to screen the autoantibodies by ELISA The antoantibodies were assayed in 98 patients with hypertension uncontrolled, 96 patients with hypertension controlled and 40 normotensives Results The intra and inter assay CVs were 0 066?0 072 and 0 097?0 101 respectively in the autoantibody positive control group, after absorbed by antigen, the absorbency ( A ) decreased 2 5 and 2 3 folds respectively In 98 patients, there were 41 patients (41 8%) with autoantibodies against AT1 receptor positive, 36 patients (36 7%) with against αl adrenergic receptor positive The positive rate of autoantibodies were significantly higher in the uncontrolled hypertension group than in controlled hypertension group (10 42% and 13 54%) and normotensives group (7 5% and 5%) , all P <0 01 Conclusions The study suggests that ELISA is an simple, specific and sensitive method to detect the autoantibodies against AT1 receptor and α1 adrenergic receptor, which is useful for monitoring the patients with hypertension
出处
《中华检验医学杂志》
CAS
CSCD
北大核心
2002年第4期226-228,共3页
Chinese Journal of Laboratory Medicine
基金
卫生部直属医疗机构临床学科重点项目 (970 72 3 8)